ArticleWorld journal of stem cells2025
Human umbilical cord mesenchymal stem cells alleviated diarrhea-type irritable bowel syndrome by improving intestinal function.
Article in World journal of stem cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Application of Human Umbilical Cord Mesenchymal Stem Cells and Their Derived Exosomes in Gastrointestinal Diseases.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIrritable bowel syndrome (IBS) is a complex bowel disorder marked by recurrent abdominal pain and irregular stools. The condition is persistent and significantly affects the quality of life of patients. In China, 5.6%-11.5% of the population has IBS, with diarrheal IBS (IBS-D) comprising about 31.5% of the total.
aimTo investigate how human umbilical cord mesenchymal stem cells (hUC-MSCs) can alleviate the symptoms with the help of an IBS-D rat model.
methodsSixty specific pathogen-free-grade male Sprague-Dawley rats were acquired and divided into five groups: Control group, model group, and three hUC-MSC groups with different doses. The model group was induced using a combination of acetic acid and binding stress. We determined the body weight of the mice; analyzed their fecal characteristics, inflammatory factors, and intestinal tissue damage; and conducted intestinal flora analyses.
resultsThe results showed that hUC-MSCs observably restored the dramatic weight loss in the rat model and also lowered the fecal water content to some extent. In addition, hUC-MSCs reduced the expression of inflammatory factors to alleviate the inflammatory response and increased the expression of intestinal barrier functional proteins to restore the colon injury by colonizing the colon tissue. In addition, hUC-MSCs were able to maintain the abundance and diversity of gut flora.
conclusionThus, hUC-MSCs can reduce the expression of inflammatory factors, improve the expression of intestinal barrier functional proteins, and maintain the abundance and diversity of intestinal flora in IBS-D by colonizing the colon tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.